Anthropic's strong financial trajectory and aggressive capital raises have driven trader consensus toward very low odds of bankruptcy in the near term. The company closed a $65 billion Series H round in May at a $965 billion post-money valuation, followed by a $35 billion private credit facility for compute infrastructure and a pending $15 billion revolving credit line ahead of a planned Nasdaq IPO as soon as October. Revenue has scaled rapidly to a $65 billion annualized run rate by July, with adjusted operating profit reported in Q2 and expected again in Q3 on gross margins above 80 percent before partner shares and training costs. Recent product launches, including Claude tools for financial advisors and life sciences verification, plus partnerships such as with Novo Nordisk for drug discovery, underscore enterprise adoption and competitive positioning against OpenAI and Google. While CEO Dario Amodei has noted the high fixed costs of frontier AI development, current metrics and investor backing point to sustained runway rather than distress.